Sanofi has acquired the American Translate Bio. This was reported by the French pharmaceutical company on Tuesday morning. Sanofi pays $ 38.00 per share Translate Bio in cash. With this, the American company, a specialist in mRNA, is valued at 3.2 billion dollars. That means a 56% Premium. The acquisition is expected to be completed in the third quarter. The board of both companies supports the acquisition. Sanofi has been working with Translate Bio since June 2018.
